Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Tablet Scoring Guidance Holds Brands, Generics To Single Standard

This article was originally published in The Tan Sheet

Executive Summary

Generic and private label industry concerns that scoring conventions could create barriers to market entry did not win out in the agency’s final tablet scoring guidance. FDA advises firms to contact the agency when questions arise about a product’s scoring being patent-protected.

You may also be interested in...



CMC Review Update: Evenity Sequence Variants, Sunosi Split-Tablet Risks, Mayzent Particle Size

Redacted drug approval packages highlight key issues in US FDA quality reviews of Amgen’s Evenity, Jazz’s Sunosi and Novartis’ Mayzent.

FDA Will Allow 10 Minor ANDA Corrections Before Refusing To Receive

Generic Drug User Fee Act refuse-to-receive draft guidance says FDA will allow sponsors to make a few small fixes to applications, but the agency will not accept any ANDAs with big problems, which will trigger automatic refuse-to-file actions.

FDA Will Allow 10 Minor ANDA Corrections Before Refusing To Receive

Generic Drug User Fee Act refuse-to-receive draft guidance says FDA will allow sponsors to make a few small fixes to applications, but the agency will not accept any ANDAs with big problems, which will trigger automatic refuse-to-file actions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel